文献速递肺栓塞与肺血管病

心室舒张压比值作为肺动脉高压治疗反应标志物

Ventricular Diastolic Pressure Ratio as a Marker of Treatment Response in Pulmonary Hypertension.
PubMed 文献 · Chest · 2017-05-17

本研究回顾性分析51例肺动脉高压患者,评估左心室舒张末压与右心室舒张末压比值(LVEDP/RVEDP)预测治疗反应的价值。治疗有效者该比值更低(1.08 vs 1.62;95%CI,0.03-0.65;

要点

  • LVEDP/RVEDP比值较低者更可能出现治疗有效反应
  • 该关联在多变量模型中独立于现有疾病严重程度标志物
  • 比值可能作为肺血管扩张剂治疗反应的预测指标

核心结论

  • LVEDP/RVEDP比值是肺动脉高压患者对肺血管扩张剂治疗反应的新型标志物,可能提供独立于现有疾病严重程度标志物的预测价值。

研究设计与样本

  • 回顾性分析INOVA Fairfax医院晚期肺病项目中同时接受左、右心导管检查的肺动脉高压患者,最终纳入51例。

主要发现

  • 21例(41.2%)出现治疗有效反应,6分钟步行试验平均改善75 m。

关键数值与推荐

  • 主要终点为1年内6分钟步行试验距离改善>35 m且未因肺动脉高压恶化住院或需追加肺动脉高压治疗的时间。

临床怎么用

  • 对肺动脉高压患者可考虑计算LVEDP/RVEDP比值,辅助预判肺血管扩张剂治疗反应。

局限性

  • 回顾性设计,样本量51例,单中心研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pulmonary hypertension (PH) is diagnosed and classified through right-sided heart catheterization, with a number of hemodynamic markers used to help guide treatment decisions. These markers may not reflect the complex remodeling of the right ventricle or the interplay between ventricles and struggle to predict treatment response. This study investigates the use of a novel marker: the ratio of left ventricular end-diastolic pressure to right ventricular end-diastolic pressure (LVEDP/RVEDP) in predicting treatment outcomes in a cohort of patients with PH. METHODS: We performed a retrospective analysis of patients with PH at INOVA Fairfax Hospital's advanced lung disease program with simultaneous left-sided and right-sided heart catheterization. The primary end point was the time to clinical improvement, defined by an improvement in distance walked on the 6-min walk test (6MWT) of > 35 m in a year without interceding hospitalization for worsening PH or the need for additional PH therapy. RESULTS: A total of 51 patients were included in the final analysis, 21 of whom (41.2%) had a salutary treatment effect with a mean improvement in the 6MWT of 75 m. Treatment responders were more likely to have a lower LVEDP/RVEDP ratio (1.08 vs 1.62; P = .051). This association persisted in the final multivariate regression model after adjustment for age and sex and controlling for severity of PH (OR, 0.17; 95% CI, 0.03-0.65; P = .024). CONCLUSIONS: The LVEDP/RVEDP ratio is a novel marker for therapeutic response in patients with PH treated with pulmonary vasodilator medications and may offer robust predictive value independent of existing markers of disease severity.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Jose A, King CS, Shlobin OA, et al. Ventricular Diastolic Pressure Ratio as a Marker of Treatment Response in Pulmonary Hypertension. Chest. 2017. PMID: 28527879. doi:10.1016/j.chest.2017.05.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。